Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.
Partner insight At the beginning of 2016, biotech equities were unable to withstand the downward pressure that put financial markets around the globe into bear territory. More recently, movements...
Round-up of diversity coverage
Latest news and analysis
Also introducing administration fee
Case opened on 13 November
Seeking assets with social and environmental impact